Latest Therapeutic hypothermia Stories
HOUSTON, May 26 2011 /PRNewswire/ -- EMIT Corporation announced today that it has received U.S. Food and Drug Administration 510(k) clearance to market the HypothermX(TM) HX100 device.
Young adult patients with genetic heart diseases, such as hypertrophic cardiomyopathy (HCM), substantially benefitted from therapeutic hypothermia, which could further extend the role for this treatment strategy in new patient populations.
Dr. George Rappardâ€™s Site is cleared to begin enrolling patients in new study. This clinical trial is the first U.S.
Mayo Clinic researchers confirmed that patients who receive therapeutic hypothermia after resuscitation from cardiac arrest have favorable chances of surviving the event and recovering good functional status.
Lowering the body temperature of patients soon after they have suffered a severe brain injury may reduce neurologic complications and improve outcomes.
Heart experts at Johns Hopkins say that physicians might be drawing conclusions too soon about irreversible brain damage in patients surviving cardiac arrest whose bodies were for a day initially chilled into a calming coma.
LOUISVILLE, Colo., Sept. 15 /PRNewswire/ -- Medivance today announced the introduction of its next-generation therapeutic temperature management device, the non-invasive Arctic SunÂ® 5000.
SAN DIEGO, California, August 16, 2010 /PRNewswire/ -- A new portable system which cools the brain via the nasal cavity may improve survival following cardiac arrest compared with standard care procedures, particularly when CPR and cooling are initiated early.
Inducing mild hypothermia is easy to implement in clinical practice and may be a valuable tool in the treatment of human sepsis patients.
Traditional methods for assessing patients after cardiac arrest may be underestimating their chances for survival and good outcomes.